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ABSTRACT 
We aimed to compare the effect of accelerated and conventional corneal collagen cross-linking (CXL) on 
visual, refractive, and topographic parameters in patients with progressive keratoconus. Between 
December 2014 and February 2016, at Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical 
Sciences, Iran, we compared 37 eyes of 21 patients treated by conventional CXL (CCXL; 3 mW/cm2 in 30 
minutes) with 34 eyes of 18 patients treated by accelerated CXL (ACXL; 18 mW/cm2 in 5 minutes) based on 
generalizing estimation equation analysis in terms of corrected distance visual acuity (CDVA), uncorrected 
distance visual acuity (UDVA), corneal endothelial cell indices, and topographic parameters before and at 3, 
6 and 12 months after the operation. The mean UDVA and spherical equivalent changes were similar in the 
two groups, but an improvement in CDVA was only observed in the CCXL group (P = 0.003). Keratometry 
(minimum and maximum) was significantly decreased in the CCXL group (P = 0.043 and P = 0.008, 
respectively). Indices of keratoconus progression—surface asymmetry index (SAI), keratoconus prediction 
index (KPI), and keratoconus index (KCI)—were significantly lower in the CCXL group than in the ACXL group 
(P = 0.002, P < 0.001, and P < 0.001, respectively). The thinnest corneal thickness (TCT) was not significantly 
different between the two groups (P = 0.15). The reduction of corneal endothelial cell density was also 
similar between the two groups; however, polymorphism and polymegethism were significantly lower in 
the ACXL group than in the CCXL group. In conclusion, we showed that although ACXL at 18 mW/cm2 
slowed keratoconus progression safely during a 1-year follow-up, CCXL at 3 mW/cm2 may be superior in 
the prevention of keratoconus progression. 
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INTRODUCTION
Keratoconus is a noninflammatory progressive 
degeneration of the cornea manifested by a reduction of 
corneal collagen and alterations in its organization [1-3]. 
It has been suggested that a greater reduction in collagen 
cross-links and pepsin digestion may result in structural 
weakness and stiffness in patients with keratoconus [4]. 
That structural instability causes visual acuity 
impairment, irregular astigmatism, progressive myopia, 
corneal thinning, and scar formation in the central 
cornea [5]. Keratoconus occurs mostly in young people 
and its prevalence is about 1 in 2000 of the general 
population [5, 6]. In 2003, Wollensak et al. presented a 
new method for the treatment of keratoconus, named 
collagen cross-linking (CXL). This technique uses a 
combination of ultraviolet-A (UVA) light and riboflavin [7] 
to form covalent bonds between collagen fibers in the 
anterior corneal stroma [8]. The traditional 
(conventional) technique of collagen cross-linking is 
widely used in the treatment of keratoconus [9]. 
However, it has some disadvantages such as diffuse 
lamellar keratitis, herpetic keratitis, and permanent 
corneal haze due to the damage caused by the UVA 
irradiation to the keratocytes, corneal endothelial cells, 
crystalline lens, and retina [10-12]. To decrease these 
harmful results, some researchers have postulated that 
the increment of intensity and decrement of irradiation 
duration could yield the same therapeutic effect, with 
higher satisfaction levels among patients and physicians 
[13]. Thus, a second-generation CXL technique was 
developed in recent years to decrease the illumination 
time and increase the intensity at 5.4-J/cm
2
 fluence [14-
16]. The results of treatment for keratoconus are not 
consistent. Therefore, we aimed to compare the effect of 
accelerated and conventional corneal CXL in patients 
with progressive keratoconus referring to Imam 
Khomeini Hospital, Ahvaz Jundishapur University of 
Medical Sciences in Iran. 
MATERIALS AND METHODS 
This retrospective study included 71 eyes from 39 
patients with progressive keratoconus referring to Imam 
Khomeini Hospital, Ahvaz Jundishapur University of 
Medical Sciences in Iran from December 2014 to 
February 2016. The criteria for enrollment were: age 10–
35 years; an increment of more than one diopter in 
keratometry in the steep meridian and an increment of 
one diopter or more in refractive errors in the last 6 
months; corneal thickness more than 400 µm at the 
thinnest point; clear cornea on slit-lamp examination; 
and lack of subepithelial and stromal scar, ocular surgery 
history, previous corneal herpetic infection, and 
pregnancy or breastfeeding. All patients were fully 
examined and allocated to conventional or accelerated 
CXL surgery. The conventional CXL (CCXL) group received 
3 mW/cm
2
 in 30 minutes (37 eyes from 21 patients) and 
the accelerated CXL (ACXL) group received 18 mW/cm
2
 in 
5 minutes (34 eyes of 18 patients). All patients were 
tested for corrected distance visual acuity (CDVA) and 
uncorrected distance visual acuity (UDVA) using an E 
chart at 3, 6, and 12 months after surgery, and the 
measurements were converted to the logMAR notation. 
Slit-lamp examination, fundoscopy, autorefractometry, 
tonometry, specular microscopy (SP-3000P Specular 
Microscope, TOPCON, Tokyo, Japan), Orb scan (Orbscan 
IIz, Technolas, Munich, Germany), and topography (TMS-
4 Topographic Modeling System, Tomey, Nagoya, Japan) 
were performed for all patients before and after the 
operation. 
Prior to procedure, topical anesthesia and a miotic 
pilocarpine drop were administered. A speculum was 
placed on the eyelids. Then, using a spatula and alcohol 
at 60, 9 mm of the central epithelial zone was removed. 
For the CCXL technique, a sponge ring was placed in the 
cornea and riboflavin 0.1% in 20% dextran 
(MedioCROSSD, Medio-Haus-Medizinprodukte GmbH, 
Kiel, Germany) was instilled to the de-epithelialized 
cornea every 3 minutes for 30 minutes, followed by 
irradiation at 3 mW/cm
2
. The corneal surface was 
irradiated at a 5-cm working distance with a 9-mm 
treatment zone for 30 minutes using a UVA system 
device (UV-X, IROC AG, Zurich, Switzerland). The 
riboflavin solution was administered to the cornea every 
5 minutes throughout the irradiation procedure. For the 
ACXL technique, isotonic riboflavin 0.1% was 
administered to the de-epithelialized cornea every 3 
minutes for 30 minutes, followed by irradiation at 18 
mW/cm
2
 using a UVA system device (CCL-365-18, MLase 
AG, Munich, Germany). The corneal surface was 
irradiated at a 5-cm working distance with a 9-mm 
treatment zone for 5 minutes. At the end of the CCXL and 
ACXL procedures, a therapeutic soft contact lens (AIR 
OPTIX, Alcon, and Fort Worth, USA) was placed on each 
cornea until complete epithelial healing. 
Chloramphenicol 0.5% (RAHA Pharmaceutical Co., 
Isfahan, Iran) four times a day for 1 week and 
betamethasone 0.1% (RAHA Pharmaceutical Co. Isfahan, 
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Iran) six times a day for 5 days and then 4 times a day for 
1 week were administered. The study was approved by 
the Institutional Review Board of Jundishapur University 
of Medical Sciences and adhered to the tenets of 
Declaration of Helsinki. The study protocol was explained 
to all patients and informed consent was obtained. The 
data were analyzed using Statistical Package for Social 
Studies version 20 (SPSS Inc., Chicago, IL). Categorical 
data are presented as numbers (%), and continuous data 
as means ± standard deviation (SD). We used the 
Student’s t-test to compare continuous variables. To 
compare the groups and to compare the times after 
intervention, the generalized estimating equation (GEE) 
was used. P < 0.05 was considered significant. 
Abbreviations 
UDVA = Uncorrected Distance Visual Acuity 
CDVA = Corrected Distance Visual Acuity 
CXL = Collagen Cross-Linking 
CCXL = Conventional Collagen Cross-Linking 
ACXL = Accelerated Collagen Cross-Linking 
SAI = Surface Asymmetry Index 
SRI = Surface Regulatory Index 
KPI = Keratoconus Prediction Index 
RESULTS 
A total of 71 eyes from 39 patients were evaluated. Two 
patients in the ACXL group were lost to follow-up and 
were excluded from the study. The mean age of the two 
groups was not significantly different (P = 0.93). At 12 
months of follow-up, there was a greater improvement 
of UCVA in the ACXL group than in the CCXL group, but 
the difference was not statistically significant (P = 0.08). 
The improvement of BCVA was significantly greater in the 
CCXL group than in the ACXL group (P = 0.006) (Table 1 
and Fig 1). 
The mean changes of manifest refraction spherical 
equivalent (MRSE) during the 12 months of follow-up 
were not significantly different in either of the two 
groups (P = 0.90). The increment of astigmatism was 
significantly lower in the ACXL group than in the CCXL 
group (P = 0.02). The changes of keratometry (maximum 
and minimum) were significant in the CCXL group (P = 
0.04) but not in the ACXL group, and there were 
significant differences between two groups (P = 0.008). 
Indices of keratoconus progression—surface asymmetry 
index (SAI), keratoconus prediction index (KPI), and 
keratoconus index (KCI)—were significantly lower in the 
CCXL group than in the ACXL group (P = 0.002, P < 0.001, 
and P < 0.001, respectively). The surface regularity index 
(SRI) was the same in the two groups. The thinnest 
corneal thickness (TCT) was significantly decreased in the 
two groups (P < 0.001), but there were no significant 
differences between the two groups (P = 0.15) (Table 2, 
Fig 2). 
The reduction of corneal endothelial cell density was 
similar in the two groups, and there were no significant 
differences between the two groups (P = 0.64) (Fig 3). 
The increment of polymorphism (P = 0.015) and 
polymegethism (P = 0.05) was significant in both groups, 
but the difference between the two groups was not 
significant (P = 0.052) (Table 2). 
 
DISCUSSION 
We showed that although ACXL at 18 mW/cm2 slowed 
keratoconus progression safely during a 1-year follow-up, 
CCXL at 3 mW/cm2 may be superior in the prevention of 
keratoconus progression.  
It is well known that CCXL can inhibit keratoconus 
progression [17, 18]. The procedure takes approximately 
1 hour per eye and several studies indicated that it is safe 
and effective [8, 9, 13, 17-25]. The ACXL procedure is 
faster, with an increase in energy without any change in 




Figure 1. Uncorrected Distance Visual Acuity (UDVA) and Best-
Corrected Distance Visual Acuity (BCVA) changes in 
Conventional Collagen Cross-Linking (CCXL) and Accelerated 
Collagen Cross-Linking. Blue Line: Uncorrected Distance Visual 
Acuity (UDVA) in the CCXL group was decreased after 3 and 6 
months and slightly increased after 12 months, yet it did not 
reach the preoperative level. Red Line: UDVA in the ACXL group 
was decreased after 3, 6, and 12 months compared to the 
preoperative level. Green Line: Corrected Distance Visual Acuity 
(CDVA) in the CCXL group was decreased after 3 and 6 months 
and increased after 12 months, yet it did not reach the 
preoperative level. Purple Line: CDVA in the ACXL group did not 
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Figure 2. Thinnest Corneal Thickness (TCT) in Conventional 
Collagen Cross-Linking (CCXL) and Accelerated Collagen Cross-
Linking. Orange Bars: mean TCT in the CCXL group was 
decreased significantly at 3 months and increased at 6 and 12 
months. Blue Bars: mean TCT in the ACXL Group was decreased 
significantly at 3 months and increased at 6 and 12 Months. 
 
 
Figure 3. Endothelial Cell Density Changes in Conventional 
Collagen cross-Linking (CCXL) and Accelerated Collagen Cross-
Linking. 
Blue Line: in the CCXL Group, the Mean Corneal Endothelial Cell 
Density was decreased after 3 months and increased after 6 
months, reaching the preoperative after 12 months. Red line: In 
the ACXL Group, the Mean Corneal Endothelial Cell Density was 
decreased after 3 months and 6 months, reaching the 
preoperative level after 12 months. 
 
That increase, to a certain extent, has been shown to be 
effective [22, 30]. In the current study, 37 eyes of 21 
patients were treated by CCXL (3 mW/cm
2
 in 30 minutes) 
and were compared with 34 eyes of 18 patients treated 
by ACXL (18 mW/cm
2






Figure 4. Left Eye Topography in a Patient from the 
Conventional Collagen Cross-Linking (CCXL) Group (Upper 
Maps) and Right Eye Topography in another Patient form the 
Accelerated Collagen Cross-Linking (ACXL) Group (Lower Maps). 
Topographic Indices at Preoperation (Right-Side Maps) and 1 
Year after the Operation (Left-Side Maps) show the Stability of 
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Table 1: Mean ± SD of the Refraction Changes during 12 Months  
Treatment group Preoperatively 3 months 6 months 12 months P-value 1 P-value 2 
UDVA (logMAR)      0.081  
Conventional 0.56 ± 0.47 0.54 ± 0.47 0.50 ± 0.48 0.49 ± 0.27 0.032  
Accelerated 0.55 ± 0.47 0.48 ± 0.40 0.44 ± 0.37 0.44 ± 0.38 0.003  
BCDVA (logMAR)      0.006  
Conventional 0.23 ± 0.32 0.18 ± 0.21 0.11 ± 0.13 0.13 ± 0.20 0.003  
Accelerated 0.19 ± 0.22 0.13 ± 0.15 0.10 ± 0.11 0.14 ± 0.17 0.011  
MRSE (D)      0.907  
Conventional -5.93 ± 5.26 -5.86 ± 4.98 -4.86 ± 4.05 -4.83 ± 3.72 0.042  
Accelerated -4.25 ± 3.64 -5.02 ± 3.65 4.79 ± 3.69- -4.80 ± 4.18 0.058  
Cylinder (D)      0.021  
Conventional 3.91 ± 2.29 4.61 ± 2.66 4.20 ± 2.42 4.03 ± 2.66 0.592  
Accelerated 3.94 ± 2.21 3.72 ± 2.08 3.83 ± 2.22 3.87 ± 2.31 0.377  
SD = Standard Deviation; logMAR = Log of the Minimum Angle of Resolution; MRSE = Manifest Refraction Spherical Equivalent; BCDVA = Best-
Corrected Distance Visual Acuity; UDVA = Uncorrected Distance Visual Acuity; D = Diopter; Accelerated = Accelerated Collagen Cross-Linking; 
Conventional = Conventional Collagen Cross-Linking. P-value 1 = 12 Months Compared to Baseline; P-value 2: Intergroup Differences at 12 
Months.   
 
Table 2: Mean ± SD of the Topographic and Specular Microscopy Index Changes during 12 Months. 
Treatment groups Preoperatively 3 months 6 months 12 months P-value 1 P-value 2 
Minimum keratometry       
Conventional 46.01±3.10 45.78±2.81 45.41±4.37 44.99±2.78 < 0.001 0.008  
Accelerated 45.00±2.36 44.68±1.61 44.14±1.34 44.92±2.34 0.992  
Maximum keratometry       
Conventional 49.42±4.78 49.46±4.77 49.65±6.13 48.85±4.67 0.006 0.043  
Accelerated 48.55±3.70 48.13±2.98 47.11±2.66 48.47±3.54 0.665  
Thinnest corneal thickness       
Conventional 440.70±58.89 347.84±58.80 359.53±72.43 378.49±73.04 <0.001 0.510  
Accelerated 431.38±51.93 382.76±64.69 408.56±62.44 405.22±61.72 0.001  
Surface asymmetry index       
Conventional 1.87±1.06 2.38±1.60 2.60±1.88 1.77±1.04 0.434 0.002  
Accelerated 2.04±1.37 1.93±1.19 1.97±1.26 1.99±1.37 0.897  
Surface regularity index       
Conventional 0.72±0.59 0.99±0.56 0.89±0.68 0.76±0.52 0.641 0.91  
Accelerated 0.66±0.46 0.61±0.35 0.60±0.34 0.68±0.49 0.515  
Keratoconus predictability index       
Conventional 0. 34±0.10 0.36±0.10 0.36±0.12 0.33±0.09 0.914 <0.001  
Accelerated 0.35±0.12 0.34±0.09 0.34±0.10 0.34±0.11 0.796  
Keratoconus index       
Conventional 62.66±34.09 65.89±33.55 58.09±37.94 57.33±36.09 0.061 <0.001  
Accelerated 57.95±36.32 58.60±33.72 58.38±35.41 56.24±38.04 0.861  
Endothelial cell density       
Conventional 2978.57±260.24 2914.08±251.53 3008.71±319.53 2958.59±271.59 0.495 0.641  
Accelerated 2887.03±244.75 2751.88±211.34 2754.76±168.83 2898.75±265.17 0.718  
Hexagonality of endothelial cells       
Conventional 54.85±14.45 48.89±13.80 49.55±14.40 53.27±12 0.588 0.015↓ 
Accelerated 61.50±11.59 57.80±12.05 57.68±9.78 57.94±9.42 0.048  
CV of endothelial cells       
Conventional 32.88±5.16 36.43±8.17 34.85±6.27 34.46±6.69 0.19 0.052  
Accelerated 31.14±4.49 29.28±5.11 32.25±7.18 32.00±5.33 0.15  
SD = Standard Deviation; Accelerated = Accelerated Collagen Cross-Linking; Conventional = Conventional Collagen Cross-Linking. CV = Coefficient 
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Then, the patients were followed for 12 months after the 
operation. The CDVA and UDVA improved significantly in 
each of the two groups during the 12 months of follow-
up. However, the difference between the two groups 
was not significant. In accordance with our findings, Cinar 
et al. reported that the two techniques were comparable 
regarding the improvement of CDVA and UDVA [23]. 
Similarly, Tomita et al. also showed that the efficacy of 
the two techniques was similar [27]. In our study, the 
improvement of CDVA and UDVA in the ACXL was similar 
to that of the study by Cinar et al. and greater than that 
in the study by Tomita et al; however, the CDVA 
remained unchanged in the latter [23]. In a trial by Shetty 
et al., the improvement of CDVA at doses of 30 mW/cm
2
 
was not significant, but was significant at 18 mW/cm
2
 or 
less. Moreover, the improvement of CDVA in ACXL was 
greater than in CCXL. In contrast to our experience, the 
UDVA in ACXL was higher than that in the CCXL [29]. 
Moreover, in another study, the difference between the 
two techniques was not significant during 18 months 
[28]. This inconsistency may be a result of the corneal 
irregularity in these patients. This issue may require 
more attention during the ocular examination. 
Therefore, it is possible that different specialists obtain 
different measurements of CDVA and UDVA at different 
times. 
The recovery of BCVA in the studies by Hashemi et al. 
and Tomita began at 6 months after the operation, which 
was similar to our study (Fig 1). In the study by Hashemi 
et al., the spherical equivalent changes were significantly 
lower in the CCXL group compared to the ACXL group 
[28]. In contrast, in our study, these changes were not 
statistically significant between two groups. However, 
the cylinder was significantly different between the two 
groups, which were in contradiction with the results 
obtained by their study [28]. This discrepancy may be 
explained by different data analysis methods and low 
repeatability of refractive errors due to optic disorders 
[28]. Several studies have indicated that the cornea 
becomes flat in both techniques [18, 22, 31]. Cinar et al. 
have noted that maximum keratometry is a guide for 
keratoconus progression, and that the maximum 
keratometry value is significantly decreased (by 1.4 in 6 
months) [23]. Hashemi et al. revealed a significant 
reduction in keratometric parameters in CCXL but not in 
ACXL, and concluded that CCXL makes cornea flatter than 
ACXL [28], which is in line with our findings. The changes 
in keratoconus parameters, SAI, KPI and KCI, were 
significantly lower in the CCXL group than in the ACXL 
group (P = 0.002, P < 0.001, and P < 0.001, respectively) 
(Fig 4). The SRI was similar in the two groups. These 
findings showed that CCXL was more effective than ACXL 
in slowing keratoconus progression. Our results were in 
agreement to those of Hafezi et al., who detected the 
linear reduction of corneal stability at a dose of 18 
mW/cm
2
; however, the difference was not significant 
when the dose was increased to 30 mW/cm
2
 [32]. We 
reported that the TCT was significantly decreased at 3 
months but increased at 6 and 12 months after the 
operation in both techniques, yet it did not reach the 
pre-operation level. In line with these findings, Shetty et 
al. revealed that both techniques decreased the TCT; 
however, the reduction of the thickness was significantly 
greater in the CCXL method than in the ACXL group [29]. 
In our study, the difference between the two techniques 
was not significant (P = 0.51). The exact reason for the 
initial reduction and increase of thickness at months 6 
and 12 is not completely understood. However, a 
possible explanation for the reduction of initial thickness 
is the compression of collagens or apoptosis of 
keratocytes [31]. Another explanation has been provided 
by Caporossi et al. They showed that the demarcation 
line is detectable up to 6 months after the surgery by the 
Orbscan due to hyperreflectivity, and this finding may be 
considered as thickness [33]. In this study, the ECD 
(endothelial cell density) was reduced during the 3 
months after the operation and returned to pre-
operation level after 12 months; the values were the 
same in both groups (P = 0.641), which was similar to the 
results of Hashemi [28], Cinar [23], and Shetty [29]. These 
findings may be related to the mild edema and haze of 
the central corneal stroma, due to the improvement 
process and migration of peripheral endothelial cells to 
the center of the cornea. Although the dose of energy 
was different between the two groups, in both 
techniques the process is the same [24] (Fig 2). The 
increase of variation among individual endothelial cell 
areas and shapes was greater in the CCXL group than in 
the ACXL group, indicating that ACXL may be safer than 
CCXL. The specular microscopy procedure takes the 
samples from one site of the cornea, which may lead to 
inter-sampling variation; moreover, in most of the 
patients, specular microscopy does not measure the 
central corneal endothelial cells, and sometimes 
peripheral cells are measured. These limitations may lead 
to different measurements of endothelial cells in one 
patient across different examinations and among 
different patients. To overcome these limitations, 
multiple sampling by the specular microscopy should be 
performed. Moreover, the duration of corneal 
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examination should take longer. The strength of this 
study was the statistical GEE analysis, which evaluated 
the correlation between eyes at different time points. To 
the best of our knowledge, all former studies have used 
repeated measures analysis. The main limitations of our 
study were the relatively small sample size and the short 
duration of follow-up (12 months). Further investigations 
with longer follow-up and larger series are required to 
validate the findings reported here. In conclusion, we 
showed that although ACXL at 18 mW/cm
2
 was a safe 
technique regarding its effect on the endothelial cells, 
CCXL at 3 mW/cm
2
 was more efficient than ACXL 
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